Teva's Generic Overdose Drug Application Sparks IP Suit

By John Kennedy (October 24, 2016, 10:03 PM EDT) -- Irish drugmaker Adapt Pharma Operations Ltd. sued Teva Pharmaceuticals USA Inc. in New Jersey federal court Friday, saying that Teva's application to sell a generic version of Adapt's Narcan nasal spray treatment for opioid overdoses infringes the drug's patent.

Adapt said that the New Drug Application for Narcan, which is the first and only U.S. Food and Drug Adminsitration-approved nasal spray for the emergency treatment of known or suspected opioid abuse, infringes a patent for which it is the exclusive licensee. The claims of the patent-in-suit, which is owned by Opiant Pharmaceuticals Inc., cover the device, the composition and the formulation...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!